Iparomlimab Tuvorlimab Application Scope

Iparomlimab Tuvorlimab (Brand name: Qibeian) is a recombinant humanized bispecific antibody targeting PD-1 and CTLA-4, designed to enhance T-cell activation and antitumor immune response.
It is indicated for the treatment of advanced or metastatic solid tumors, including non–small cell lung cancer (NSCLC) and melanoma, particularly in patients who have failed prior immunotherapy or chemotherapy.

Iparomlimab Tuvorlimab Characteristics

Ingredients:
Properties: Clear to slightly opalescent, colorless to pale yellow solution for injection
Packaging Specification: 50 mg × 1 vial/box
Storage: Store at 2–8 °C; protect from light; do not freeze
Expiry Date: 24 months from manufacturing date
Executive Standard: In accordance with NMPA biological product specifications
Approval Number: To be confirmed (NMPA)
Date of Revision: To be confirmed
Manufacturer: Akeso Biopharma Co., Ltd. (China)

Guidelines for the Use of Qibeian

Dosage and Administration:
- Recommended Dose: 5 mg/kg every 3 weeks, continued until disease progression or unacceptable toxicity.
- Administration: Dilute with 0.9% NaCl solution; infuse over 60 minutes under medical supervision.
- Missed Dose: Administer as soon as possible; do not double the next dose.
Adverse Reactions:
- Common Adverse Reactions: Fatigue, rash, pruritus, diarrhea, and decreased appetite.
- Serious Adverse Reactions: Immune-related hepatitis, pneumonitis, colitis, endocrinopathies (e.g., hypothyroidism).
Contraindications: Known hypersensitivity to Iparomlimab Tuvorlimab or any excipient in the formulation.
Precautions:
- Monitor for immune-related adverse events (irAEs).
- Interrupt or discontinue treatment if Grade 3–4 toxicity occurs.
- Use with caution in patients with autoimmune diseases.
- Safety in pregnancy or lactation not established.

Iparomlimab Tuvorlimab Interactions

No clinically significant drug–drug interactions reported to date.
Avoid concomitant use with other immune checkpoint inhibitors unless prescribed by a specialist.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.